Global Primary Biliary Cirrhosis Drug
Global Primary Biliary Cirrhosis Drug

Primary Biliary Cirrhosis Drug Comprehensive Study by Type (Budesonide, FFP-104, GSK-2330672, MBX-8025, NGM-282, Others), Application (Clinic, Hospital, Others), Tests (Computed Tomography (CT), Ultrasound, Magnetic Resonance Imaging (MRI), Needle Biopsy) Players and Region - Global Market Outlook to 2026

Primary Biliary Cirrhosis Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 206 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Primary Biliary Cirrhosis Drug Market Overview:
Primary Biliary Cirrhosis is also known as Primary biliary cholangitis (PBC), is basically a autoimmune disease of the liver. It generates from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. It is caused by a combination of subtle differences in how the immune system works. As the bile ducts get damages and injured, it causes bile to build up in the liver. This further damages the liver and may lead to scarring (cirrhosis). There are certain drugs which are been used to treat this problems. The medications which are been used to treat primary biliary cirrhosis include ursodeoxycholic acid (UDCA), rarely colchicine (Colcrys), and sometimes certain immunosuppressive medications, such as corticosteroids.

Growth Drivers
  • Growing Prevalence of Obesity and Diabetes Problems in People Across the World
  • Number of Cases with Viral Infections Like Hepatitis B, C, D, and Alcoholism

Market Trends
  • Rising Non-alcoholic Fatty Liver Disease
  • High Risk of Liver Cirrhosis in Young Adults and Women

Roadblocks
  • Lengthy Process Involved in Drug and Treatment Research
  • Complications Involved with Primary Biliary Cirrhosis Treatment

Opportunities
  • Continuous Research and Development in Liver Cirrhosis Drugs
  • Advancements in Biliary Cirrhosis Treatment Imaging Devices

Challenges
  • Expensive Liver Transplantation


Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are AlbireoPharma (United States), CymaBay Therapeutics, Inc. (United States), Dr. Falk Pharma GmbH (Germany), Enanta Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Intercept Pharmaceuticals, Inc. (United States), Johnson & Johnson (United States), MediGene AG (Germany) and NGM Biopharmaceuticals, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Primary Biliary Cirrhosis Drug market by 2026. Considering Market by Tests, the sub-segment i.e. Computed Tomography (CT) will boost the Primary Biliary Cirrhosis Drug market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Primary Biliary Cirrhosis Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Primary Biliary Cirrhosis Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Primary Biliary Cirrhosis Drug Suppliers, Primary Biliary Cirrhosis Treatment Providers, Research and Development Institutes, Potential Investors, Hospitals, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Budesonide
  • FFP-104
  • GSK-2330672
  • MBX-8025
  • NGM-282
  • Others
By Application
  • Clinic
  • Hospital
  • Others
By Tests
  • Computed Tomography (CT)
  • Ultrasound
  • Magnetic Resonance Imaging (MRI)
  • Needle Biopsy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Obesity and Diabetes Problems in People Across the World
      • 3.2.2. Number of Cases with Viral Infections Like Hepatitis B, C, D, and Alcoholism
    • 3.3. Market Challenges
      • 3.3.1. Expensive Liver Transplantation
    • 3.4. Market Trends
      • 3.4.1. Rising Non-alcoholic Fatty Liver Disease
      • 3.4.2. High Risk of Liver Cirrhosis in Young Adults and Women
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Primary Biliary Cirrhosis Drug, by Type, Application, Tests and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Primary Biliary Cirrhosis Drug (Value)
      • 5.2.1. Global Primary Biliary Cirrhosis Drug by: Type (Value)
        • 5.2.1.1. Budesonide
        • 5.2.1.2. FFP-104
        • 5.2.1.3. GSK-2330672
        • 5.2.1.4. MBX-8025
        • 5.2.1.5. NGM-282
        • 5.2.1.6. Others
      • 5.2.2. Global Primary Biliary Cirrhosis Drug by: Application (Value)
        • 5.2.2.1. Clinic
        • 5.2.2.2. Hospital
        • 5.2.2.3. Others
      • 5.2.3. Global Primary Biliary Cirrhosis Drug by: Tests (Value)
        • 5.2.3.1. Computed Tomography (CT)
        • 5.2.3.2. Ultrasound
        • 5.2.3.3. Magnetic Resonance Imaging (MRI)
        • 5.2.3.4. Needle Biopsy
      • 5.2.4. Global Primary Biliary Cirrhosis Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Primary Biliary Cirrhosis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AlbireoPharma (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CymaBay Therapeutics, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dr. Falk Pharma GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Enanta Pharmaceuticals, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Intercept Pharmaceuticals, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MediGene AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NGM Biopharmaceuticals, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Primary Biliary Cirrhosis Drug Sale, by Type, Application, Tests and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Primary Biliary Cirrhosis Drug (Value)
      • 7.2.1. Global Primary Biliary Cirrhosis Drug by: Type (Value)
        • 7.2.1.1. Budesonide
        • 7.2.1.2. FFP-104
        • 7.2.1.3. GSK-2330672
        • 7.2.1.4. MBX-8025
        • 7.2.1.5. NGM-282
        • 7.2.1.6. Others
      • 7.2.2. Global Primary Biliary Cirrhosis Drug by: Application (Value)
        • 7.2.2.1. Clinic
        • 7.2.2.2. Hospital
        • 7.2.2.3. Others
      • 7.2.3. Global Primary Biliary Cirrhosis Drug by: Tests (Value)
        • 7.2.3.1. Computed Tomography (CT)
        • 7.2.3.2. Ultrasound
        • 7.2.3.3. Magnetic Resonance Imaging (MRI)
        • 7.2.3.4. Needle Biopsy
      • 7.2.4. Global Primary Biliary Cirrhosis Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Primary Biliary Cirrhosis Drug: by Type(USD Million)
  • Table 2. Primary Biliary Cirrhosis Drug Budesonide , by Region USD Million (2015-2020)
  • Table 3. Primary Biliary Cirrhosis Drug FFP-104 , by Region USD Million (2015-2020)
  • Table 4. Primary Biliary Cirrhosis Drug GSK-2330672 , by Region USD Million (2015-2020)
  • Table 5. Primary Biliary Cirrhosis Drug MBX-8025 , by Region USD Million (2015-2020)
  • Table 6. Primary Biliary Cirrhosis Drug NGM-282 , by Region USD Million (2015-2020)
  • Table 7. Primary Biliary Cirrhosis Drug Others , by Region USD Million (2015-2020)
  • Table 8. Primary Biliary Cirrhosis Drug: by Application(USD Million)
  • Table 9. Primary Biliary Cirrhosis Drug Clinic , by Region USD Million (2015-2020)
  • Table 10. Primary Biliary Cirrhosis Drug Hospital , by Region USD Million (2015-2020)
  • Table 11. Primary Biliary Cirrhosis Drug Others , by Region USD Million (2015-2020)
  • Table 12. Primary Biliary Cirrhosis Drug: by Tests(USD Million)
  • Table 13. Primary Biliary Cirrhosis Drug Computed Tomography (CT) , by Region USD Million (2015-2020)
  • Table 14. Primary Biliary Cirrhosis Drug Ultrasound , by Region USD Million (2015-2020)
  • Table 15. Primary Biliary Cirrhosis Drug Magnetic Resonance Imaging (MRI) , by Region USD Million (2015-2020)
  • Table 16. Primary Biliary Cirrhosis Drug Needle Biopsy , by Region USD Million (2015-2020)
  • Table 17. South America Primary Biliary Cirrhosis Drug, by Country USD Million (2015-2020)
  • Table 18. South America Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 19. South America Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 20. South America Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 21. Brazil Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 22. Brazil Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 23. Brazil Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 24. Argentina Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 25. Argentina Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 26. Argentina Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 27. Rest of South America Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 30. Asia Pacific Primary Biliary Cirrhosis Drug, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 34. China Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 35. China Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 36. China Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 37. Japan Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 38. Japan Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 39. Japan Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 40. India Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 41. India Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 42. India Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 43. South Korea Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 44. South Korea Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 45. South Korea Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 46. Taiwan Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 47. Taiwan Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 48. Taiwan Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 49. Australia Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 50. Australia Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 51. Australia Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 55. Europe Primary Biliary Cirrhosis Drug, by Country USD Million (2015-2020)
  • Table 56. Europe Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 57. Europe Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 58. Europe Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 59. Germany Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 60. Germany Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 61. Germany Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 62. France Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 63. France Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 64. France Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 65. Italy Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 66. Italy Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 67. Italy Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 68. United Kingdom Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 71. Netherlands Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 72. Netherlands Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 73. Netherlands Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 74. Rest of Europe Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 77. MEA Primary Biliary Cirrhosis Drug, by Country USD Million (2015-2020)
  • Table 78. MEA Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 79. MEA Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 80. MEA Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 81. Middle East Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 82. Middle East Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 83. Middle East Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 84. Africa Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 85. Africa Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 86. Africa Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 87. North America Primary Biliary Cirrhosis Drug, by Country USD Million (2015-2020)
  • Table 88. North America Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 89. North America Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 90. North America Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 91. United States Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 92. United States Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 93. United States Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 94. Canada Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 95. Canada Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 96. Canada Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 97. Mexico Primary Biliary Cirrhosis Drug, by Type USD Million (2015-2020)
  • Table 98. Mexico Primary Biliary Cirrhosis Drug, by Application USD Million (2015-2020)
  • Table 99. Mexico Primary Biliary Cirrhosis Drug, by Tests USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Primary Biliary Cirrhosis Drug: by Type(USD Million)
  • Table 110. Primary Biliary Cirrhosis Drug Budesonide , by Region USD Million (2021-2026)
  • Table 111. Primary Biliary Cirrhosis Drug FFP-104 , by Region USD Million (2021-2026)
  • Table 112. Primary Biliary Cirrhosis Drug GSK-2330672 , by Region USD Million (2021-2026)
  • Table 113. Primary Biliary Cirrhosis Drug MBX-8025 , by Region USD Million (2021-2026)
  • Table 114. Primary Biliary Cirrhosis Drug NGM-282 , by Region USD Million (2021-2026)
  • Table 115. Primary Biliary Cirrhosis Drug Others , by Region USD Million (2021-2026)
  • Table 116. Primary Biliary Cirrhosis Drug: by Application(USD Million)
  • Table 117. Primary Biliary Cirrhosis Drug Clinic , by Region USD Million (2021-2026)
  • Table 118. Primary Biliary Cirrhosis Drug Hospital , by Region USD Million (2021-2026)
  • Table 119. Primary Biliary Cirrhosis Drug Others , by Region USD Million (2021-2026)
  • Table 120. Primary Biliary Cirrhosis Drug: by Tests(USD Million)
  • Table 121. Primary Biliary Cirrhosis Drug Computed Tomography (CT) , by Region USD Million (2021-2026)
  • Table 122. Primary Biliary Cirrhosis Drug Ultrasound , by Region USD Million (2021-2026)
  • Table 123. Primary Biliary Cirrhosis Drug Magnetic Resonance Imaging (MRI) , by Region USD Million (2021-2026)
  • Table 124. Primary Biliary Cirrhosis Drug Needle Biopsy , by Region USD Million (2021-2026)
  • Table 125. South America Primary Biliary Cirrhosis Drug, by Country USD Million (2021-2026)
  • Table 126. South America Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 127. South America Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 128. South America Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 129. Brazil Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 130. Brazil Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 131. Brazil Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 132. Argentina Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 133. Argentina Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 134. Argentina Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 135. Rest of South America Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 136. Rest of South America Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 137. Rest of South America Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 138. Asia Pacific Primary Biliary Cirrhosis Drug, by Country USD Million (2021-2026)
  • Table 139. Asia Pacific Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 140. Asia Pacific Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 141. Asia Pacific Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 142. China Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 143. China Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 144. China Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 145. Japan Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 146. Japan Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 147. Japan Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 148. India Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 149. India Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 150. India Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 151. South Korea Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 152. South Korea Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 153. South Korea Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 154. Taiwan Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 155. Taiwan Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 156. Taiwan Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 157. Australia Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 158. Australia Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 159. Australia Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 163. Europe Primary Biliary Cirrhosis Drug, by Country USD Million (2021-2026)
  • Table 164. Europe Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 165. Europe Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 166. Europe Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 167. Germany Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 168. Germany Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 169. Germany Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 170. France Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 171. France Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 172. France Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 173. Italy Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 174. Italy Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 175. Italy Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 176. United Kingdom Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 177. United Kingdom Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 178. United Kingdom Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 179. Netherlands Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 180. Netherlands Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 181. Netherlands Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 182. Rest of Europe Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 183. Rest of Europe Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 184. Rest of Europe Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 185. MEA Primary Biliary Cirrhosis Drug, by Country USD Million (2021-2026)
  • Table 186. MEA Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 187. MEA Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 188. MEA Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 189. Middle East Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 190. Middle East Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 191. Middle East Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 192. Africa Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 193. Africa Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 194. Africa Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 195. North America Primary Biliary Cirrhosis Drug, by Country USD Million (2021-2026)
  • Table 196. North America Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 197. North America Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 198. North America Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 199. United States Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 200. United States Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 201. United States Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 202. Canada Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 203. Canada Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 204. Canada Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 205. Mexico Primary Biliary Cirrhosis Drug, by Type USD Million (2021-2026)
  • Table 206. Mexico Primary Biliary Cirrhosis Drug, by Application USD Million (2021-2026)
  • Table 207. Mexico Primary Biliary Cirrhosis Drug, by Tests USD Million (2021-2026)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Primary Biliary Cirrhosis Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Primary Biliary Cirrhosis Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Primary Biliary Cirrhosis Drug: by Tests USD Million (2015-2020)
  • Figure 7. South America Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 8. Asia Pacific Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 9. Europe Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 10. MEA Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 11. North America Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 12. Global Primary Biliary Cirrhosis Drug share by Players 2020 (%)
  • Figure 13. Global Primary Biliary Cirrhosis Drug share by Players (Top 3) 2020(%)
  • Figure 14. Global Primary Biliary Cirrhosis Drug share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AlbireoPharma (United States) Revenue, Net Income and Gross profit
  • Figure 17. AlbireoPharma (United States) Revenue: by Geography 2020
  • Figure 18. CymaBay Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. CymaBay Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Dr. Falk Pharma GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Dr. Falk Pharma GmbH (Germany) Revenue: by Geography 2020
  • Figure 22. Enanta Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Enanta Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Intercept Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Intercept Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 29. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 30. MediGene AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. MediGene AG (Germany) Revenue: by Geography 2020
  • Figure 32. NGM Biopharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. NGM Biopharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Global Primary Biliary Cirrhosis Drug: by Type USD Million (2021-2026)
  • Figure 35. Global Primary Biliary Cirrhosis Drug: by Application USD Million (2021-2026)
  • Figure 36. Global Primary Biliary Cirrhosis Drug: by Tests USD Million (2021-2026)
  • Figure 37. South America Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 38. Asia Pacific Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 39. Europe Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 40. MEA Primary Biliary Cirrhosis Drug Share (%), by Country
  • Figure 41. North America Primary Biliary Cirrhosis Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • AlbireoPharma (United States)
  • CymaBay Therapeutics, Inc. (United States)
  • Dr. Falk Pharma GmbH (Germany)
  • Enanta Pharmaceuticals, Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Intercept Pharmaceuticals, Inc. (United States)
  • Johnson & Johnson (United States)
  • MediGene AG (Germany)
  • NGM Biopharmaceuticals, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation